Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
High-dose aflibercept works in the real world, too. A Danish study of 95 treatment-naive eyes found that first-line aflibercept 8 mg improved vision by 3.6 letters and reduced retinal thickness by ~85 µm over 300 days. Patients with worse baseline vision saw the biggest gains — up to 16 letters — though injection intervals remained shorter than in clinical trials.
A real-world Danish study is offering encouraging evidence that high-dose aflibercept (8 mg) holds up outside the controlled setting of clinical trials. Researchers at Aalborg University Hospital tracked 95 treatment-naive eyes with diabetic macular edema (DME) over 300 days, finding meaningful improvements in both vision and retinal anatomy with first-line use of the drug.
On average, patients gained 3.6 letters of best-corrected visual acuity and saw retinal thickness drop by nearly 85 µm by day 300. The benefits were especially striking in patients who started with poorer vision — those with baseline acuity of 60 letters or lower gained an impressive 16.2 letters on average.
By the Numbers
Why it matters: These findings suggest high-dose aflibercept can deliver real benefits for DME patients in everyday clinical practice — not just in tightly controlled trials. However, the short injection intervals and persistent macular edema signal that many patients will need sustained, long-term treatment rather than early treatment breaks, prompting clinicians to plan accordingly.
